Propanc Biopharma closes $1.0M private placement of Series C Preferred Stock to Hexstone Capital

Propanc Biopharma, Inc.

Hexstone purchased 100 Series C Preferred shares at $10,000 each plus a warrant for up to 9,900 additional shares; total cash $1,000,099.
Series C Preferred convertible into common at the lesser of $5.00 fixed price or 85% of lowest trading price over a specified period.
Board authorized up to 9,900 shares of Series C Preferred via Certificate of Designation filed November 4, 2025.
Securities issued under private placement exemption per Section 4(a)(2) and Regulation D.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Propanc Biopharma, Inc.: Filed Certificate of Designation creating Series C Preferred Stock as an amendment to the Certificate of Incorporation (effective 2025-11-04).

Change: charter amendment
Effective: 2025-11-04

Exact text from the filing

On November 4, 2025, the Company amended its Certificate of Incorporation and filed a Certificate of Designation with the Delaware Secretary of State that authorized the issuance of up to 9,900 shares of a new series of preferred stock, par value $0.01 per share, designated as “Series C Preferred Stock” for which the Board established the rights, preferences and limitations thereof.

View on SEC.gov

259 governance changes filed in the last 30 days. Browse all governance changes →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-021567

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.